Crucially, B2A exhibits strong specificity toward BMPs, with no response to other growth factors such as fibroblast growth factor-2 (FGF-2), TGF-1, and vascular endothelial growth factor
Long-standing reputation among independent researchers
Twelve peptides were formally removed from the FDAs Category 2 restricted list on April 23, 2026, including BPC-157, TB-500, GHK-Cu (injectable), Semax, and others
This product is sold strictly as a research-use reagent
D 2 homodimers, 59,60 are currently being actively developed
A 2016 phase 1B clinical trial, investigating the efficacy of NSI-189 in a randomized, placebo-controlled study design, indicated significant effects of the drug as orally administered to individuals suffering from MDD either once, twice or three times per day